The FDA will decide whether to approve Pfizer’s vaccine candidate for respiratory syncytial virus in August. The shot is administered to expectant mothers and protects infants from severe disease through their first six months of life, the drugmaker said in a Feb. 21 news release.
Read the full post on Becker's Hospital Review - Healthcare News
